BNF June 2018 update
This update contains 11 significant changes, 5 new preparations and 6 dose changes.
Asthma, chronic: updated guidance on management.
Brodalumab for treating moderate to severe plaque psoriasis [NICE guidance]
Cabozantinib for treating medullary thyroid cancer [NICE guidance].
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen [NICE guidance].
Immunoglobulins: updated guidance for Varicella-zoster immunoglobulin.
Obeticholic acid (Ocaliva®): risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring [MHRA/CHM advice].
Obinutuzumab for untreated advanced follicular lymphoma [NICE guidance].
Quinine: clarification of parenteral dose for the treatment of malaria [dose reduction necessary if parenteral treatment is required for more than 48 hours].
Regorafenib for previously treated advanced hepatocellular carcinoma [NICE guidance].
Vaccines: updated guidance for Hepatitis A Vaccine.
Vaccines for travel: updated guidance on Hepatitis A.
Bosutinib [update to dose in renal impairment].
Candesartan cilexetil [clarification of maximum daily dose in heart failure].
Haloperidol [clarification of continuous subcutaneous dose for nausea and vomiting in palliative care].
Nivolumab [doses for monotherapy].
AirFluSal® preparations [fluticasone with salmeterol], Fasenra® [benralizumab], Hemlibra® preparations [tocilizumab], Rydapt® [midostaurin].
For further details on changes in the BNF click on changes.